PDS Biotechnology Corporation (NASDAQ:PDSB) Q1 2023 Earnings Conference Call May 15, 2023 8:00 AM ET
Company Participants
Gabby DeGravina - Investor Relations
Frank Bedu-Addo - Chief Executive Officer
Matt Hill - Chief Financial Officer
Lauren V. Wood - Chief Medical Officer
Conference Call Participants
Louise Chen - Cantor Fitzgerald
Leland Gershell - Oppenheimer
Andy Fleszar - B. Riley Securities
Robert LeBoyer - Noble Capital Markets
James Molloy - Alliance Global Partners
Operator
Hello, and welcome to the PDS Biotechnology First Quarter 2023 Earnings Conference Call and Webcast. [Operator Instructions] A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded.
It's now my pleasure to turn the call over to your host, Gabby DeGravina, Investor Relations. Please go ahead, Gabby.
Gabby DeGravina
Good morning, and welcome to PDS Biotechnology's first quarter 2023 earnings conference call and audio webcast.
On the call from the company are Dr. Frank Bedu-Addo, Chief Executive Officer; Dr. Lauren V. Wood, Chief Medical Officer; and Matt Hill, Chief Financial Officer.
Earlier this morning, PDS Biotech issued a press release announcing financial results for the quarter ended May 31 -- March 31, 2023. We encourage everyone to read the press release as well as PDS Biotech's report on Form 10-Q, which will be filed with the SEC shortly. The company's press release is available on the PDS website at pdsbiotech.com.
In addition, this conference call is being webcast and will be archived on the company website for future reference.
Before we begin, we need to remind everyone that on today's call, the company will be making forward-looking statements regarding regulatory and clinical candidate development plans as well as research activities. Certain information in this presentation may include forward-looking statements including within the meaning of Section 21E of United States Securities Exchange Act of 1934 as amended and Section 27A of the United States Securities Act of 1933 as amended, concerning PDS Biotechnology Corporation and other matters.
These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise based on current beliefs of the company's operations, as well as assumptions made by and information currently available to management. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in PDS Biotech's most recent filing to SEC.